OBJECTIVE: To develop and validate a predictive model to estimate the probability of being nonadherent to topical glaucoma medications. DESIGN: Prospective cohort study. PARTICIPANTS: Patients being treated with once-daily prostaglandin eye drops. METHODS: A predictive model for nonadherence was developed from the Travatan Dosing Aid (TDA) study (n = 196) using stepwise logistic regression. The performance of the TDA-derived model was assessed using a separate cohort of subjects from the Automated Dosing Reminder Study (ADRS; n = 407). The assessment was based on regression coefficients, discrimination, and calibration. We also developed a scoring system from the TDA-derived model to simplify the estimation of risk for clinical use. MAIN OUTCOME MEASURES: Usage of drops was monitored electronically for 3 months in both studies. Adherence was calculated as the percentage of days on which a dose was taken within 4 hours of the average dosing time for that patient. Nonadherence was defined as taking ≤ 75% prescribed doses within a window starting 2 weeks after the baseline visit until 2 weeks before the follow-up visit. RESULTS: Six factors, including younger age, black race, worse general health status, shorter duration of glaucoma medication therapy, lower self-reported adherence, and admitting to not following doctors' orders, were associated with being nonadherent and were included in the predictive model. The coefficients for the TDA-derived and the ADRS-derived predictive models were similar. The risk scoring system developed from the TDA study had good discrimination (area under the receiver operating characteristic curve of 0.80) and calibration (Hosmer-Lemeshow goodness-of-fit test, P = 0.102) when applied to the ADRS population. CONCLUSIONS: The TDA-derived predictive model for nonadherence performed well in an independent population. A risk scoring system was developed using demographic data and patient responses to 4 questions to provide an estimate of the probability of being nonadherent.
OBJECTIVE: To develop and validate a predictive model to estimate the probability of being nonadherent to topical glaucoma medications. DESIGN: Prospective cohort study. PARTICIPANTS: Patients being treated with once-daily prostaglandin eye drops. METHODS: A predictive model for nonadherence was developed from the Travatan Dosing Aid (TDA) study (n = 196) using stepwise logistic regression. The performance of the TDA-derived model was assessed using a separate cohort of subjects from the Automated Dosing Reminder Study (ADRS; n = 407). The assessment was based on regression coefficients, discrimination, and calibration. We also developed a scoring system from the TDA-derived model to simplify the estimation of risk for clinical use. MAIN OUTCOME MEASURES: Usage of drops was monitored electronically for 3 months in both studies. Adherence was calculated as the percentage of days on which a dose was taken within 4 hours of the average dosing time for that patient. Nonadherence was defined as taking ≤ 75% prescribed doses within a window starting 2 weeks after the baseline visit until 2 weeks before the follow-up visit. RESULTS: Six factors, including younger age, black race, worse general health status, shorter duration of glaucoma medication therapy, lower self-reported adherence, and admitting to not following doctors' orders, were associated with being nonadherent and were included in the predictive model. The coefficients for the TDA-derived and the ADRS-derived predictive models were similar. The risk scoring system developed from the TDA study had good discrimination (area under the receiver operating characteristic curve of 0.80) and calibration (Hosmer-Lemeshow goodness-of-fit test, P = 0.102) when applied to the ADRS population. CONCLUSIONS: The TDA-derived predictive model for nonadherence performed well in an independent population. A risk scoring system was developed using demographic data and patient responses to 4 questions to provide an estimate of the probability of being nonadherent.
Authors: Felipe A Medeiros; Robert N Weinreb; Pamela A Sample; Cintia F Gomi; Christopher Bowd; Jonathan G Crowston; Linda M Zangwill Journal: Arch Ophthalmol Date: 2005-10
Authors: Betsy Sleath; Alan L Robin; David Covert; John E Byrd; Gail Tudor; Bonnie Svarstad Journal: Ophthalmology Date: 2006-02-03 Impact factor: 12.079
Authors: David S Friedman; Harry A Quigley; Laurie Gelb; Jason Tan; Jay Margolis; Sonali N Shah; Elizabeth E Kim; Thom Zimmerman; Steven R Hahn Journal: Invest Ophthalmol Vis Sci Date: 2007-11 Impact factor: 4.799
Authors: David S Friedman; Steven R Hahn; Laurie Gelb; Jason Tan; Sonali N Shah; Elizabeth E Kim; Thom J Zimmerman; Harry A Quigley Journal: Ophthalmology Date: 2008-03-05 Impact factor: 12.079
Authors: Man-Hin Lui; Jason Chun Ho Lam; Yi Lee Kwong; Tak Siu Wong; Pak Long Cheung; Sherri Shun Yan Lai; Pak Lun Yuen; Wai Yiu Lam; Ho Yan Chan; Yiu Fai Wong; Jimmy Shiu Ming Lai; Kendrick Co Shih Journal: Int J Ophthalmol Date: 2017-02-18 Impact factor: 1.779
Authors: Paula Anne Newman-Casey; Leslie M Niziol; Brenda W Gillespie; Nancy K Janz; Paul R Lichter; David C Musch Journal: Ophthalmology Date: 2020-01-10 Impact factor: 12.079
Authors: Paula Anne Newman-Casey; Olivia J Killeen; Morgan Renner; Alan L Robin; Paul Lee; Michele Heisler Journal: Telemed J E Health Date: 2018-04-23 Impact factor: 3.536
Authors: Andrew Camp; Sarah R Wellik; Jonathan H Tzu; William Feuer; Kristopher L Arheart; Ananth Sastry; Anat Galor Journal: Cont Lens Anterior Eye Date: 2015-02-24 Impact factor: 3.077
Authors: Cecilia N Hollenhorst; Vanessa Elliott; Michele Heisler; Kevin Schneider; Ken Resnicow; Paula Anne Newman-Casey Journal: Ophthalmol Glaucoma Date: 2020-05-07
Authors: Paula Anne Newman-Casey; Leslie M Niziol; Paul P Lee; David C Musch; Kenneth Resnicow; Michele Heisler Journal: Ophthalmol Glaucoma Date: 2020-04-30